These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 29790851

  • 1. RIG-I enhances interferon-α response by promoting antiviral protein expression in patients with chronic hepatitis B.
    Wu S, Lin J, Fu Y, Ou Q.
    Antivir Ther; 2018; 23(7):575-583. PubMed ID: 29790851
    [Abstract] [Full Text] [Related]

  • 2. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.
    Han M, Li Y, Wu W, Zhang Y, Yan W, Luo X, Ning Q.
    Antiviral Res; 2017 Nov; 147():75-85. PubMed ID: 28988797
    [Abstract] [Full Text] [Related]

  • 3. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Nov; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 4. Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.
    Luo S, Cassidy W, Jeffers L, Reddy KR, Bruno C, Howell CD.
    Clin Gastroenterol Hepatol; 2005 May; 3(5):499-506. PubMed ID: 15880320
    [Abstract] [Full Text] [Related]

  • 5. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, Jiang J, Hou J, Han M, Ning Q.
    Antivir Ther; 2015 May; 20(6):591-602. PubMed ID: 25814467
    [Abstract] [Full Text] [Related]

  • 6. ADAR1 Stimulation by IFN-α Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response.
    Li T, Yang X, Li W, Song J, Li Z, Zhu X, Wu X, Liu Y.
    Mol Ther; 2021 Mar 03; 29(3):1335-1348. PubMed ID: 33279720
    [Abstract] [Full Text] [Related]

  • 7. [Myxovirus resistance protein A (MxA) induces the expression of interferon-stimulated genes in HepG2 cells by enhancing the activity of the interferon-stimulated response element (ISRE)].
    Yang K, Pan Y, Liu P, Yu F, Wei X, Zhang F, Wang Q.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Aug 03; 40(8):704-709. PubMed ID: 39215668
    [Abstract] [Full Text] [Related]

  • 8. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Aug 03; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 9. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Aug 03; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 10. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus.
    Domagalski K, Pawłowska M, Zaleśna A, Pilarczyk M, Rajewski P, Halota W, Tretyn A.
    World J Gastroenterol; 2016 Nov 07; 22(41):9186-9195. PubMed ID: 27895405
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov 07; 23(11):826-31. PubMed ID: 26743242
    [Abstract] [Full Text] [Related]

  • 12. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L, Cariti G, Di Perri G, D'Avolio A.
    J Med Virol; 2016 Nov 07; 88(11):1953-9. PubMed ID: 27017932
    [Abstract] [Full Text] [Related]

  • 13. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL.
    J Infect Dis; 2016 Jan 15; 213(2):224-32. PubMed ID: 26216905
    [Abstract] [Full Text] [Related]

  • 14. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z, Li X, Shi C, Zhang M, Chen R, Wu W, Hou Q, Ke W, Fan T, Wen Z, Hao X, Qu N.
    Mol Med Rep; 2015 Jan 15; 11(1):427-33. PubMed ID: 25324041
    [Abstract] [Full Text] [Related]

  • 15. [Relationship between the suppressor of cytokine signaling 3 expression and antiviral efficacy of nucleos(t)ide and interferon alpha therapy for chronic hepatitis B].
    Wang YL, Wu WY, You J, Yan WM, Luo XP, Ning Q, Han MF.
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan 20; 27(1):27-32. PubMed ID: 30685920
    [Abstract] [Full Text] [Related]

  • 16. [The influence of HBV and its antigens on the expressions of JAK-STAT signal transduction pathway molecules and antiviral proteins of IFN alpha].
    Guan SH, Yang K, Lu MJ, Lu YP, Yang DL.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jun 20; 19(6):440-4. PubMed ID: 22053375
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.
    Yeh ML, Huang JF, Yu ML, Chuang WL.
    Expert Rev Gastroenterol Hepatol; 2021 Apr 20; 15(4):427-435. PubMed ID: 33338385
    [Abstract] [Full Text] [Related]

  • 18. Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.
    Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, Kudo M.
    Antivir Ther; 2018 Apr 20; 23(6):513-521. PubMed ID: 29438098
    [Abstract] [Full Text] [Related]

  • 19. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro.
    Zhang Q, Wang Y, Wei L, Jiang D, Wang JH, Rao HY, Zhu L, Chen H, Fei R, Cong X.
    J Gastroenterol Hepatol; 2008 Nov 20; 23(11):1747-61. PubMed ID: 17559358
    [Abstract] [Full Text] [Related]

  • 20. Duck RIG-I restricts duck enteritis virus infection.
    Huo H, Wang Y, Wang D, Wang Y, Chen X, Zhao L, Chen H.
    Vet Microbiol; 2019 Mar 20; 230():78-85. PubMed ID: 30827409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.